Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2811-2813.
Prepublished online as a Blood First Edition Paper on June 29, 2006; DOI 10.1182/blood-2006-04-017400.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-04-017400v1
108/8/2811    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kovitz, C.
Right arrow Articles by Cortes, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kovitz, C.
Right arrow Articles by Cortes, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted April 19, 2006
Accepted June 3, 2006

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

Craig Kovitz, Hagop Kantarjian, Guillermo Garcia-Manero, Lynne V Abruzzo, and Jorge Cortes*

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

* Corresponding author; email: jcortes{at}mdanderson.org.

During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Ph-negative cells. These are frequently transient and their clinical consequence is unclear. Although some reports have suggested these abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria. We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other two developed high risk MDS which rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although rare, these findings highlight the need for close monitoring of patients with CML treated with imatinib.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. Quintas-Cardama and J. Cortes
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
Blood, February 19, 2009; 113(8): 1619 - 1630.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
A. Fabarius, M. Giehl, B. Rebacz, A. Kramer, O. Frank, C. Haferlach, P. Duesberg, R. Hehlmann, W. Seifarth, and A. Hochhaus
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
Haematologica, August 1, 2008; 93(8): 1145 - 1154.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
V. Bedell, S. J. Forman, K. Gaal, V. Pullarkat, L. M. Weiss, and M. L. Slovak
Successful Application of a Direct Detection Slide-Based Sequential Phenotype/Genotype Assay Using Archived Bone Marrow Smears and Paraffin Embedded Tissue Sections
J. Mol. Diagn., November 1, 2007; 9(5): 589 - 597.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Jabbour, H. M. Kantarjian, L. V. Abruzzo, S. O'Brien, G. Garcia-Manero, S. Verstovsek, J. Shan, M. B. Rios, and J. Cortes
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Blood, October 15, 2007; 110(8): 2991 - 2995.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood, October 15, 2007; 110(8): 2828 - 2837.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
C. A. Schiffer
BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
N. Engl. J. Med., July 19, 2007; 357(3): 258 - 265.
[Full Text] [PDF]


Home page
haematolHome page
A. Fabarius, C. Haferlach, M. C. Muller, P. Erben, T. Lahaye, M. Giehl, O. Frank, W. Seifarth, R. Hehlmann, and A. Hochhaus
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
Haematologica, June 1, 2007; 92(6): 834 - 837.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
S. Branford
Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice
Hematology, January 1, 2007; 2007(1): 376 - 383.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020